Advertisement
RVTY vs WAT
Which Stock Would AI Choose? Revvity (RVTY) vs. Waters (WAT) Stock Comparison
Key Takeaways
- Revvity (RVTY) and Waters (WAT) operate in the life sciences and diagnostics sector, with RVTY offering broader health sciences solutions and WAT focusing on analytical instruments and chromatography.
- Recent market activity shows RVTY trading near $113 with modest year-to-date gains, while WAT has held around $377 amid sector volatility.
- Both companies reported earnings beats in their latest quarters, supporting stable fundamentals despite broader market pressures on healthcare stocks.
- RVTY has pursued portfolio optimization including a planned divestiture, whereas WAT maintains a more concentrated high-margin product lineup.
- Sector exposure overlaps in diagnostics and research tools, creating comparable sensitivity to research spending and regulatory environments.
- Relative performance reflects trade-offs between RVTY's growth initiatives and WAT's established profitability metrics.
Introduction
Revvity (RVTY) and Waters (WAT) represent two established players in the life sciences tools and diagnostics space. Investors and traders evaluating healthcare equipment and services often compare these names to assess relative positioning within a sector influenced by research budgets, regulatory shifts, and technological adoption. This comparison highlights differences in business focus, recent share price behavior, and market sentiment that may appeal to those constructing diversified portfolios or monitoring sector rotation opportunities.
RVTY Overview and Recent Performance
Revvity (RVTY), formerly PerkinElmer, provides health sciences solutions including instruments, reagents, and software for diagnostics and life sciences applications. In recent weeks, the stock has traded in a range near $112-$114, reflecting measured investor response to its first-quarter results that showed revenue growth and earnings beats. Portfolio adjustments, such as the announced intent to divest a portion of its China immunodiagnostics business, have contributed to ongoing sentiment around operational focus. Broader market activity in healthcare has tempered volatility, with the shares maintaining positions relative to moving averages amid steady sector flows.
WAT Overview and Recent Performance
Waters (WAT) specializes in analytical instruments, particularly liquid chromatography and mass spectrometry systems used in pharmaceutical, environmental, and food testing. Recent market activity has seen the stock hover around the $370-$380 level, supported by its reputation for high operating margins and recurring revenue streams. Performance in the period has aligned with sector trends, with limited specific catalysts beyond general earnings visibility and demand stability in core end markets. Sentiment remains anchored to the company's consistent execution in a competitive instrumentation landscape.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots from a much larger library of hundreds of bots that trade thousands of different tickers. Only those demonstrating strong suitability for prevailing market conditions earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, and performance statistics, allowing users to explore options with varying risk profiles and historical outcomes. This resource provides traders with transparent metrics to evaluate automated approaches across multiple assets. Explore the full selection on the Trending AI Robots page.
Head-to-Head Comparison
Revvity (RVTY) pursues a diversified model across diagnostics and life sciences, offering exposure to both consumables and instruments, while Waters (WAT) concentrates on premium analytical tools with notably higher operating margins. Recent momentum for RVTY has incorporated growth from organic revenue increases and strategic divestitures, contrasting with WAT’s emphasis on margin stability and recurring service revenue. Risk factors include RVTY’s exposure to international regulatory and divestiture execution variables versus WAT’s sensitivity to capital equipment cycles in research and development spending. Sector exposure overlaps significantly in life sciences, yet RVTY’s broader diagnostics reach introduces additional healthcare policy considerations. Market sentiment reflects these contrasts, with investors weighing RVTY’s transformation initiatives against WAT’s established profitability and market positioning.
Tickeron AI Verdict
Based on observable factors such as trend consistency in recent quarters, earnings stability, and relative positioning within the sector, Tickeron’s AI would currently assign a modest probabilistic edge to Waters (WAT) for its demonstrated margin resilience and focused product strength. Revvity (RVTY) remains competitive through its growth initiatives and portfolio refinement. Outcomes would depend on execution of upcoming results and broader market conditions affecting both names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RVTY is a Hold and WAT is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RVTY’s FA Score shows that 3 FA rating(s) are green whileWAT’s FA Score has 1 green FA rating(s).
- RVTY’s FA Score: 3 green, 2 red.
- WAT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RVTY’s TA Score shows that 4 TA indicator(s) are bullish while WAT’s TA Score has 5 bullish TA indicator(s).
- RVTY’s TA Score: 4 bullish, 4 bearish.
- WAT’s TA Score: 5 bullish, 3 bearish.
Price Growth
RVTY (@Medical Specialties) experienced а -0.11% price change this week, while WAT (@Medical Specialties) price change was +3.17% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +4.45%. For the same industry, the average monthly price growth was +1.71%, and the average quarterly price growth was +19.48%.
Reported Earning Dates
RVTY is expected to report earnings on Nov 02, 2026.
WAT is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Medical Specialties (+4.45% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| RVTY | WAT | RVTY / WAT | |
| Capitalization | 12.4B | 38.9B | 32% |
| EBITDA | 773M | 991M | 78% |
| Gain YTD | 15.364 | 4.278 | 359% |
| P/E Ratio | 53.55 | 100.27 | 53% |
| Revenue | 2.9B | 3.77B | 77% |
| Total Cash | N/A | 462M | - |
| Total Debt | 3.35B | 5.57B | 60% |
RVTY | WAT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 71 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 90 | |
SMR RATING 1..100 | 88 | 85 | |
PRICE GROWTH RATING 1..100 | 19 | 48 | |
P/E GROWTH RATING 1..100 | 22 | 4 | |
SEASONALITY SCORE 1..100 | 5 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RVTY's Valuation (15) in the Medical Specialties industry is somewhat better than the same rating for WAT (73). This means that RVTY’s stock grew somewhat faster than WAT’s over the last 12 months.
WAT's Profit vs Risk Rating (90) in the Medical Specialties industry is in the same range as RVTY (100). This means that WAT’s stock grew similarly to RVTY’s over the last 12 months.
WAT's SMR Rating (85) in the Medical Specialties industry is in the same range as RVTY (88). This means that WAT’s stock grew similarly to RVTY’s over the last 12 months.
RVTY's Price Growth Rating (19) in the Medical Specialties industry is in the same range as WAT (48). This means that RVTY’s stock grew similarly to WAT’s over the last 12 months.
WAT's P/E Growth Rating (4) in the Medical Specialties industry is in the same range as RVTY (22). This means that WAT’s stock grew similarly to RVTY’s over the last 12 months.
| RVTY | WAT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 70% | N/A |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 74% |
| Momentum ODDS (%) | 1 day ago 63% | 1 day ago 64% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 54% |
| TrendWeek ODDS (%) | 1 day ago 67% | 1 day ago 63% |
| TrendMonth ODDS (%) | 1 day ago 68% | 1 day ago 60% |
| Advances ODDS (%) | 6 days ago 64% | 13 days ago 63% |
| Declines ODDS (%) | 9 days ago 67% | 2 days ago 64% |
| BollingerBands ODDS (%) | 1 day ago 66% | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 64% | N/A |
Advertisement